IFM Tre

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Gary Glick’s fourth biotechnology firm, Scorpion Therapeutics , emerged from stealth mode on 26 October with $108m to develop small molecules that are safer, more tolerable and provide deeper, more d

Just four years after its foundation, Ireland's Inflazome Ltd. and its portfolio of NLRP3 inhibitors targeting a wide range of chronic inflammatory conditions has been acquired by Roche Holding AG

Novartis AG has been active in non-alcoholic steatohepatitis (NASH) development and deal-making in recent years, but its $80m upfront commitment to Pliant Therapeutics for a preclinical alpha V bet